Immunic (IMUX)

Immunic (IMUX) Stock Price & Analysis


IMUX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.11 - $11.76
Previous Close$1.43
Average Volume (3M)752.10K
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$77.30M
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)-0.4
Nov 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.44
Shares Outstanding44,595,383
10 Day Avg. Volume254,246
30 Day Avg. Volume752,103
Standard Deviation0.25
Financial Highlights & Ratios
Price to Book (P/B)0.87
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Price Target Upside237.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $1.11 and its highest was $11.76 in the past 12 months.
    What is Immunic’s market cap?
    Currently, no data Available
    When is Immunic’s upcoming earnings report date?
    Immunic’s upcoming earnings report date is Nov 09, 2023 which is in 41 days.
      How were Immunic’s earnings last quarter?
      Immunic released its earnings results on Aug 03, 2023. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.525 by -$0.015.
        Is Immunic overvalued?
        According to Wall Street analysts Immunic’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Immunic pay dividends?
          Immunic does not currently pay dividends.
          What is Immunic’s EPS estimate?
          Immunic’s EPS estimate is -$0.55.
            How many shares outstanding does Immunic have?
            Immunic has 44,595,383 shares outstanding.
              What happened to Immunic’s price movement after its last earnings report?
              Immunic reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.525. Following the earnings report the stock price went down -1.389%.
                Which hedge fund is a major shareholder of Immunic?
                Among the largest hedge funds holding Immunic’s share is Omega Fund Management, LLC. It holds Immunic’s shares valued at 4M.


                  Immunic Stock Smart Score

                  The Immunic stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.


                  Top 5 ETFs holding IMUX

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold IMUX. The ETFs are listed according to market value of IMUX within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Kezar Life Sciences

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis